Fuzeon Accelerated Simultaneous Access Program (Fuzeon ASAP)
Roche and Trimeris are pleased to announce the Fuzeon® (enfuvirtide) Accelerated Simultaneous Access Program (Fuzeon ASAP). This program is designed to provide immediate access to up to a 60-day supply of Fuzeon for patients who are prescribed Fuzeon together in a regimen with an investigational agent in expanded access, when deemed medically appropriate by a physician. Access to a broad range of patient support services to assist patients in successful therapy initiation and follow-up will also be available through this program. We hope that the availability of Fuzeon ASAP will assist physicians and patients in both the planning and simultaneous initiation of treatment changes involving Fuzeon and investigational agents obtained through an expanded access program.
For patients who are starting treatment with Fuzeon in combination with an investigational drug in expanded access, Fuzeon ASAP will provide:
Up to a 60-day supply of Fuzeon
This includes an immediate shipment of a 30-day supply at no cost to the patient or clinician. One additional 30-day supply can be made available if reimbursement is still pending.
Reimbursement Assistance Services
To help facilitate continued access to Fuzeon, a reimbursement counselor will verify patient prescription benefits, evaluate reimbursement options, and assist with the completion of prior authorizations, where necessary. Additionally, an application to the indigent Patient Assistance Program* will be provided, if needed.
Upon request, support programs for patients will be provided, including home nurse visits to supplement initial injection training provided to the patient by the physician.
Upon request, adherence programs will be provided to help facilitate successful continuation of therapy and assistance throughout the duration of treatment with Fuzeon.
If you are interested in enrolling any patients in the Fuzeon ASAP or would like to obtain more information regarding this program, please call the Fuzeon Answer Center at 1-877-4 Fuzeon (877-438-9366).
Diego Miralles, M.D., Medical Director, Trimeris
James A. Thommes, M.D., Medical Director, Virology-HIV, Roche Pharmaceuticals
* Roche Patient Assistance Program (PAP) provides products to patients who do not have prescription drug coverage and do not qualify for government funded programs. Applicants to the PAP are considered on an individual basis and must meet Roche PAP eligibilty guidelines. Not all patients will qualify for the PAP.
Roche and Trimeris reserve the right to discontinue or restrict enrollment in Fuzeon ASAP at any time.